The new services provide rapid production of antibody drug conjugates (ADCs) for best candidate selection.
On Oct. 8, 2019, MilliporeSigma introduced its ADC Express services for the rapid production of antibody drug conjugates (ADCs), which can reduce the time needed to produce development-grade constructs for target molecule identification. With more than 70% of ADC projects outsourced to contract manufacturing and development organizations, this service enhances MilliporeSigma’s offering of process development, analytical development, testing services, and manufacturing or supply of linkers, cytotoxins/payloads, and conjugates.
MilliporeSigma’s established platform technology can efficiently turn an antibody, linker, and payload into an ADC. The company offers a platform approach to ADC constructs and bioconjugation, resulting in increased flexibility and speed, it stated.
The ADC Express services include:
• Mini-prep scale: 10–20 mg ADC construct ± column purification
• Medium-prep scale: ~100 mg ADC ± column purification
• Certificate of testing with key quality attributes, including ADC concentration, payload density/ drug antibody ratio (DAR) and monomer/aggregate content, and free residual payload
For companies that have a rich pipeline of monoclonal antibodies and want to enter the ADC space, this express services allows them to obtain ADCs without having to invest in potent handling capabilities, according to the company. Companies can either bring their own linker technology or procure a linker payload from MilliporeSigma. The company’s comprehensive ADC service portfolio combines the crucial steps of drug development and production: mAb solutions, linker, payload, and the final conjugation-all from a single source.